ZyVersa enters $10M equity purchase agreement with Williamsburg Venture Holdings to fund VAR 200 clinical development

ZyVersa Therapeutics, Inc.

Up to $10M of common stock; company controls timing and amount of sales over 24-month term.
Purchase price set at 94% of lowest VWAP during three trading days after each sale clears.
2.5% commitment fee in common shares, with piggyback registration rights; no warrants or derivatives.
Funds intended to progress clinical development of Cholesterol Efflux Mediator TM VAR 200 for chronic kidney disease.
Issuance capped at 19.99% of outstanding shares unless stockholder approval is obtained.

item 1.01item 3.02item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.